Supernus Announces Third Quarter 2026 Financial Results
Supernus posted record Q3 2026 total revenues of $226.8 million, up 18% year-over-year, driven by 29% growth across its four growth products. The company swung to GAAP operating earnings of $21.2 million from a $60.2 million loss a year ago, with diluted EPS of $0.35 versus $(0.80). ONAPGO net sales surged 151% to $17.1 million and received seven years of FDA orphan-drug exclusivity; Qelbree grew 12% to $90.8 million and ZURZUVAE collaboration revenue more than doubled to $41.7 million. Management raised stand-alone FY26 guidance to $875-$900 million in revenue and $160-$180 million in adjusted operating earnings.
Key figures
- Eps
- 0.35
- Revenue
- 226800000
- Guidance
- FY26 total revenues $875-$900M (raised from $860-$890M); GAAP operating loss $(5)-$(40)M (improved from $(20)-$(50)M); adjusted operating earnings $160-$180M (raised from $150-$180M)
- Revenue Yoy
- 18%
- Net earnings q3
- 20913000
- Onapgo net sales
- 17100000
- Operating income
- 21179000
- Gocovri net sales
- 42600000
- Qelbree net sales
- 90800000
- Growth product revenue
- 192200000
- Expected cost synergies
- 125000000
- Growth product revenue yoy
- 29%
- Adjusted operating earnings q3
- 55200000
- Cash and marketable securities
- 359500000
- Zurzuvae collaboration revenue
- 41700000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.